Endpoints News
Plus: Cigna's rebate shakeup Read in browser
Endpoints News
Tuesday, 28 October 2025
Thank you for reading, dupa dupackia!
basic
UPGRADE
44% of 2025 health tech funds go to provider operations
SVB Report: Investments in operations surpass other healthtech sectors
sponsored by Silicon Valley Bank
At-home testing’s evolution
It had been years since I last saw Julia Cheek in person.
Cheek, the CEO of at-home testing company Everlywell, reminded me when I last saw her in 2019 the company was making about $40 million in revenue from its cash-pay business. Then the Covid-19 pandemic, of course, completely upended the at-home testing market.
But more recently, Everlywell made headlines when a court ordered Walgreens to pay the company $1 billion as part of a dispute around Covid-19 tests. Walgreens ultimately paid Everlywell $595 million, but the lawsuit factored into the price at which Sycamore Partners took the retail pharmacy private. 
That outcome sets Everlywell up with a lot of cash as it pushes deeper into what it’s been working on over the last three years: helping health plans, through testing and telehealth visits, close care gaps that influence how much plans get paid by the government. Today, Cheek told me, Everlywell is mostly a payer business, rather than a direct-to-consumer business. (In 2021, Everlywell bought Home Access Health and PWNHealth as part of that push.) 
The initial idea for it came when the head of star ratings at Humana saw Cheek on “Shark Tank” in 2017, then reached out to set up a pilot to close care gaps important to those star ratings, a measure of health plan quality.
“If we really want to have the maximum impact for the maximum number of people, we have to be able to go this path,” Cheek said to me at HLTH, where we caught up earlier this month.
Next, Cheek said, Everlywell is looking to add cancer screenings like multi-cancer early detection tests and colon cancer screenings to the services it offers.  
- Lydia
Here’s what’s new
'Poor children of very rich parents': How Verily plans to grow out of Alphabet's shadow
In the last decade, Ver­i­ly, Al­pha­bet’s life sci­ences arm, has dab­bled in every­thing from mos­qui­toes to mon­i­tor­ing waste­water to in­sur­ance. But more recently, it’s been — at long last — sharpening its focus and divesting units.
Cigna says it will move to end drug rebates beginning in 2027
Cigna said it will move away from re­ceiv­ing drug re­bates, an opaque part of the US drug pric­ing for­mu­la that has drawn in­creased scruti­ny from fed­er­al and state law­mak­ers.
Insured
26993

The average annual family premiums for employer sponsored health insurance rose to nearly $27,000, according to an October survey from KFF. The average family premiums increased by 6% compared to 2024, KFF found. 

This week in health Тech
Ensemble Health, a company that does healthcare revenue cycle management, hired banks ahead of a potential 2026 IPO or a sale, Business Insider reports.
Teladoc's chief financial officer Mala Murthy is stepping down after six years with the company. The telehealth company reports its third-quarter earnings tomorrow.
Epic is ending its Workshop program, which took stakes in startups like Abridge, Axios reports.
Honey Health raised $7.8 million to work with medical groups and health systems to automate administrative workflows like notes prep. Pelion Ventures led the round.
John Carroll
Editor & Founder
Arsalan Arif
Publisher & Founder
Igor Yavych
Architect & Founder
Valentin Manov
Creative Director
Ryan McRae
Chief Revenue Officer
Amanda Florez
Chief of Staff
Drew Armstrong
Executive Editor
Liam Chua
Chief Technical Officer
Jaimy Lee
Deputy Editor
Lydia R. Pflanzer
Deputy Editor
Zachary Brennan
Senior Editor
Max Gelman
Senior Editor
Julie O'Meara
Executive Director, Brand Partnerships
Melissa Nazzaro
Executive Director, Brand Partnerships
James Cherrick